English, Article edition: Cost Efficacy of Tazobactam/Piperacillin versus Imipenem/Cilastatin in the Treatment of Intra-Abdominal Infection Eva Susanne Dietrich; Bjorn Schubert; Winfried Ebner; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118935
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Efficacy of Tazobactam/​Piperacillin versus Imipenem/​Cilastatin in the Treatment of Intra-Abdominal Infection
Author
  • Eva Susanne Dietrich
  • Bjorn Schubert
  • Winfried Ebner
  • Franz Daschner
Physical Description
  • article
Notes
  • Objective: To compare the cost, efficacy and cost efficacy of tazobactam/​ piperacillin and imipenem/​cilastatin in the treatment of intra-abdominal infection. Design: The analysis was retrospective and based on a decision tree. Effectiveness data were obtained from 19 published clinical trials. Direct costs were quantified per patient from the time the decision was made to administer the antibacterial to the end of the first course of treatment or the end of a subsequent course of treatment, if required. The primary end-point was the cost per successfully treated patient. The cost per life saved was also analysed. Various follow-up times were taken into account. Perspective: German National Health Insurance funds. Study population: 1744 patients with intra-abdominal infection. Interventions: Tazobactam/​piperacillin (total daily dosage of 13.5 g/​day) and imipenem/​cilastatin (total daily dosage of 1.5 to 4 g/​day). The mean duration of treatment varied from 5.5 to 8.2 days for tazobactam/​piperacillin and 5 to 9.4 days for imipenem/​cilastatin. Main outcome measure and results: Compared with imipenem/​cilastatin, treatment with tazobactam/​piperacillin was more effective and the overall treatment costs were lower. In the base-case analysis, the cost-efficacy ratio (cost per successfully treated patient) was 7881 German deutschmarks (DM) for tazobactam/​ piperacillin and DM11 390 for imipenem/​cilastatin. The incremental cost-efficacy ratio (per life saved) varied between -DM72 567 and -DM350 738 for tazobactam/​ piperacillin. Sensitivity analyses revealed that the results were robust against various assumptions on cost parameters, clinical outcomes and length of treatment. All costs reflect 1998 values; $US1 =​ DM1.85. Conclusions: This study suggests that compared with imipenem/​cilastatin, tazobactam/​piperacillin is more cost efficacious in the treatment of intra-abdominal infections and that it offers a cost advantage through fewer relapses and lower daily therapeutic costs.
  • Antibacterials, Cost analysis, Imipenem/​cilastatin, Intra abdominal infections, Pharmacoeconomics, Tazobactam/​piperacillin
  • RePEc:wkh:phecon:v:19:y:2001:i:1:p:79-94
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment